Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Hepregen Announces Appointment of Dr. Michael Holsapple

Published: Wednesday, August 07, 2013
Last Updated: Wednesday, August 07, 2013
Bookmark and Share
Appointment adds respected leader in toxicology to Hepregen’s senior management team, reflecting ongoing commitment of Hepregen’s strategic investor, Battelle Memorial Institute.

Hepregen Corporation has announced the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development.

This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute (“Battelle”), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle.

Following a successful 13-year academic career, Dr. Holsapple was leader of the Immunotoxicology and Respiratory Toxicology groups at Dow Chemical for eight years, after which, from 2002 to 2011, he served as the Executive Director of the Health and Environmental Sciences Institute (HESI), the global branch of the International Life Sciences Institute (ILSI) in Washington, DC.

He joined Battelle in 2011 as a Senior Leader Research in systems toxicology. Dr. Holsapple received the Society of Toxicology (SOT) Achievement Award in 1992.

In recognition of his contributions to immunotoxicology, he received the Vos Award: Career Achievement in Immunotoxicology in 2009.

Dr. Holsapple has served on Council for the SOT, and on Council for the American College of Toxicology (ACT). He was elected a ‘fellow’ in the Academy of Toxicological Sciences (ATS) in 2006, and a member of the Board of Trustees of the ATS in 2013. He is also a past President of the SOT.

Dr. Holsapple stated, “Hepregen has become the leader in next generation in vitro micro-liver products. Joining the Company’s outstanding team of scientists and commercially experienced senior managers is without a doubt an exceptional opportunity to participate in development of products that can transform the pharmaceutical, cosmetics and chemical industries.”

“Mike’s incredibly extensive scientific and organizational background in the field of toxicology provides Hepregen with an unmatched resource,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer, adding, “He brings a wealth of knowledge and experience to our emerging global enterprise.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
Agreement provides for European sales of Hepregen's HepatoPac® and HepatoMune™ proprietary products by SOLVO and provision of services using these products.
Wednesday, June 24, 2015
QTS and Hepregen Execute Co-Development and Co-Marketing Agreement
Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.
Tuesday, November 04, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos